白芍总甙对豚鼠结肠平滑肌作用机制的研究

目的 :探讨白芍总甙 (TGP)对离体豚鼠结肠平滑肌的作用方式及对结肠平滑肌中 P物质 (SP)和血管活性肠肽 (VIP)释放的影响。方法 :观察不同剂量 TGP及工具药对离体结肠肌收缩活性的效应及利用 SABC法检测结肠平滑肌中 SP和血管 VIP的变化。结果 :TGP使豚鼠结肠离体平滑肌收缩积分和时间显著性增加 ,且收缩效应的改变具有剂量依赖性。平滑肌中 SP的反应显著性增强。结论 :TGP可通过延长结肠收缩时间 ,增强结肠收缩幅度而调节结肠运动 ,SP是 TGP作用的递质之一。     

纤维肌痛综合征疼痛症状临床疗效观察

目的比较阿米替林基础治疗,加用米氮平,加用白芍总苷胶囊及联合用药4组对纤维肌痛综合征(FS)的疗效。方法分别测定记录4组治疗前,治疗1、3个月末时,疼痛程度目测标尺法(VAS)评分、90项症状自评量表(SCL—90)、Hamilton焦虑量表(HAMA)、Hamilton抑郁量表(HAMD)的变化比较。结果①B组1、3个月末SCL—90下降值明显低于A组(P<0.05);②C组1个月末VAS下降值明显低于B组(P<0.05);③D组1、3个月末的VAS/SCL—90下降值明显低于A、B、C组(P<0.05);④本研究中使用的HAMA、HAMD量表,观察中与临床症状、体征变化缺乏一致性。结论①在阿米替林等药物治疗FS基础上,联合小剂量米氮平及白芍总苷胶囊能明显提高疗效,且较安全。②SCL—90量表引入FS疗效评定,对FS症状的量化、活动度观察可能有益。③HAMA和HAMD量表不适用于FS诊断及疗效观察。     

白芍总苷对阿尔茨海默病的保护作用及机制的研究

目的探讨白芍总苷（total glucosides of paeony,TGP）对阿尔茨海默病（AD）的保护作用及其作用机制。方法实验共分为7组,分别为正常对照组（Control组）、模型组[连二亚硫酸钠（Na2S2O4）缺氧无保护组]及TGP各干预组（剂量分别为50、100、200、400、800mg／L）。采用Na2S2O4建立人神经母细胞瘤（SK—N—SH）细胞缺氧损伤模型,Na2S2O4于不同浓度TGP干预1h后加入,作用16h。利用倒置相差显微镜观察各组SK-N—SH细胞生长及形态的变化;采用四甲基偶氮唑盐（MTr）微量酶反应比色法测定各组SK—N—SH细胞的存活率;利用蛋白免疫印迹（western blot）法检测SK—N-SH细胞中半胱氨酸天冬氨酸蛋白酶-3（Caspase-3）的表达水平。结果形态学研究显示,正常对照组SK-N-SH细胞呈圆形,较少有突起,为贴壁细胞,折光性较强;模型组多数细胞肿胀,折光度减弱,最终细胞成团、漂浮,并有许多细胞崩解物,TGP各浓度组均较模型组细胞数量较多,折光性明显增强,细胞裂解碎片减少,多数细胞重新贴壁伸展;TGP100、200、400、800mg／L干预组能够有效改善SK-N—SH细胞缺氧损伤造成的细胞死亡率的增加;TGP50、100、200、400、800mg／L干预明显抑制SK—N—SH细胞缺氧损伤造成的Caspase-3蛋白表达的增加。结论TGP对AD具有明显的保护作用,其作用机制与通过调控Caspase-3蛋白的表达影响神经细胞的凋亡相关。     

白芍总甙对应激大鼠下丘脑一垂体一肾上腺轴和免疫功能的调节

本文以血浆皮质酮（ＣＳ）、促肾上腺皮质激素（ＡＣＴＨ）和β－内啡肽（β－ＥＮＤ）含量为指标，观察了白芍总甙（ＴＧＰ）对不同状态（正常或不同应激）的大鼠下丘脑－垂体－肾上腺轴（ＨＰＡＡ）及其免疫功能的调节作用。结果表明，ＴＧＰ对正常大鼠的ＨＰＡＡ呈现小剂量（１２．５～５０．０ｍｇ·ｋｇ－１）兴奋（血浆ＣＳ含量升高）和大剂量（１００～２００ｍｇ·ｋｇ－１）抑制（血浆ＣＳ含量降低）的剂量依赖性调节作用。其次，ＴＧＰ可兴奋轻度应激（２０℃水游泳）大鼠的ＨＰＡＡ和抑制重度应激（４℃水游泳或２４ｈ束缚）大鼠的ＨＰＡＡ，使过高的血浆ＣＳ、ＡＣＴＨ和β－ＥＮＤ含量降低，提示ＴＧＰ对应激大鼠ＨＰＡＡ呈现轴机能依赖性的调节作用。此外，ＴＧＰ在降低束缚应激大鼠血浆ＣＳ、ＡＣＴＨ和β－ＥＮＤ水平的同时，上调受抑大鼠脾淋巴细胞ＣｏｎＡ增殖反应和腹腔Ｍ释放Ｈ２Ｏ２，提示ＴＧＰ的免疫调节作用可能与其调节ＨＰＡＡ的功能有关。     

白芍总甙对大白鼠睡眠节律的影响

白芍总甙(TGP)每日ig 50mg·kg~(-1),连续7d可延长正常大鼠慢波睡眠(SWS)的持续时间.并能使咖啡因(12.5 mg·kg~(-1),ip)诱导的失眠大鼠睡眠各参数恢复到接近正常水平。TGP 50mg·kg~(-1)×3d)还可明显延长游泳大鼠(水温25±1℃.游泳时间30min)SWS和异相睡眠的总时间。上述实验结果提示TGP可改善不同功能状态下的大鼠睡眠。     

白芍总苷胶囊结合尿激酶治疗急性缺血性脑梗死临床研究

目的：评价白芍总苷胶囊结合尿激酶治疗急性缺血性脑梗死(acute cerebral ischemic stroke, ACIS)的疗效。方法将符合入选标准的152例ACIS患者采用随机数字表法分为对照组77例、观察组75例。对照组静脉注射尿激酶溶栓，观察组在对照组基础上口服或鼻饲白芍总苷胶囊。全部患者均经溶栓治疗24 h，排除脑出血或凝血机制障碍后，给予抗血小板聚集、降血脂、营养神经、改善循环等治疗。2组均连续治疗14 d。依据美国国立卫生研究院卒中量表(National Institute of Health Stroke Scale, NIHSS)进行神经功能缺损评分，采用改良的Rankin量表(Modified Rankin Scale, mRS)评价神经功能的恢复状况，采用日常生活能力指数量表(Barthel)评价患者的日常生活能力。结果治疗后7 d，NIHSS评分下降≥4分者观察组28例(37.3%)、对照组12例(15.6%)，2组比较差异有统计学意义(χ2＝8.181，P＝0.004)；观察组NIHSS评分[(8.3±2.2)分比(9.9±2.5)分，t＝4.192]低于对照组(P＜0.05)。治疗后14 d， mRS评分≤4分者观察组68例(90.7%)、对照组51例(66.2%)，2组比较差异有统计学意义(χ2＝11.945， P＝0.001)；观察组 mRS 评分[(2.3±0.9)分比(2.9±1.1)分，t＝3.684]低于对照组(P＜0.01)，Barthel 指数[(88.7±16.2)分比(77.5±15.2)分，t＝4.401]高于对照组(P＜0.01)。结论白芍总苷胶囊结合尿激酶溶栓治疗可有效改善ACIS患者神经功能缺损状态，提高患者日常生活能力，疗效优于单纯使用尿激酶。     

阿维A联合白芍总苷治疗寻常型银屑病的疗效观察

目的:观察阿维A联合白芍总苷治疗寻常型银屑病的临床疗效。方法:81例符合条件的患者随机分为2组,对照组40例口服阿维A0.5mg·kg-1·d-1,症状好转后改为0.1～0.2mg·kg-1·d-1;治疗组41例在对照组的基础上加服白芍总苷0.6mg,tid。2组均外用冰黄肤乐霜。疗程均为8周。治疗前、后检查2组患者的血尿常规、肝肾功能及血脂含量,并观察患者的不良反应。结果:治疗组有效率为90.2%,对照组为62.5%,2组有效率差异有显著性(P<0.05);治疗组患者的不良反应显著低于对照组(P<0.05)。结论:阿维A联合白芍总苷治疗寻常型银屑病近期疗效明显,且不良反应少,安全性高。     

Effects of total glucosides from paeony (Paeonia lactiflora Pall) roots on experimental atherosclerosis in rats

Ethnopharmacological relevance

Total glucosides of paeony (TGP), compounds extracted from the roots of Paeonia lactiflora Pall, have been used as an anti-inflammatory drug for the treatment of rheumatoid arthritis (RA) in China. Inflammation plays a critical role in the development of atherosclerotic vascular disease. Risk of cardiovascular diseases is significantly higher in patients with RA than in normal population. It has a great significance to study the effects of TGP on atherosclerosis.

Aim of the study

To investigate the effects of TGP on atherosclerosis induced by excessive administration of vitamin D and cholesterol in rats and study the mechanisms involved.

Materials and methods

Atherosclerosis was induced by excessive administration of vitamin D and cholesterol in rats. TGP was intragastrically administered for 15 weeks. The serum concentrations of total cholesterol (TC), triglyceride (TG), low density lipoprotein-cholesterol (LDL-C) and high density lipoprotein-cholesterol (HDL-C) were measured by automatic biochemistry analyzer. Apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB) were determined by immunoturbidimetry method, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and C-reactive protein (CRP) were measured by enzyme-linked immunosorbent assay (ELISA) method. The morphological changes of aorta were observed with optical microscopy.

Results

Compared to controls, TGP significantly lowered the serum level of TC, TG, LDL-C, ApoB, TNF-alpha, IL-6 and CRP, increased the ratios of HDL-C/LDL-C and ApoA1/ApoB, decreased the intima-media thickness (IMT) of abdominal aortal wall and improved the morphological change of the aorta.

Conclusions

TGP may attenuate the development of atherosclerotic disease. The beneficial effects are associated with its lowering blood lipids and inhibiting the expression of inflammatory cytokines.     

Variant call concordance between two laboratory-developed,solid tumor targeted genomic profiling assays using distinct workflows and sequencing instruments

Targeted genomic profiling (TGP) using massively parallel DNA sequencing is becoming the standard methodology in clinical laboratories for detecting somatic variants in solid tumors. The variety of methodologies and sequencing platforms in the marketplace for TGP has resulted in a variety of clinical TGP laboratory developed tests (LDT). The variability of LDTs is a challenge for test-to-test and laboratory-to-laboratory reliability. At the University of Vermont Medical Center (UVMMC), we validated a TGP assay for solid tumors which utilizes DNA hybridization capture and complete exon and selected intron sequencing of 29 clinically actionable genes. The validation samples were run on the Illumina MiSeq platform. Clinical specificity and sensitivity were evaluated by testing samples harboring genomic variants previously identified in CLIA-approved, CAP accredited laboratories with clinically validated molecular assays. The Molecular Laboratory at Dartmouth Hitchcock Medical Center (DHMC) provided 11 FFPE specimens that had been analyzed on AmpliSeq Cancer Hotspot Panel version 2 (CHPv2) and run on the Ion Torrent PGM. A Venn diagram of the gene lists from the two institutions is shown. This provided an excellent opportunity to compare the inter-laboratory reliability using two different target sequencing methods and sequencing platforms. Our data demonstrated an exceptionally high level of concordance with respect to the sensitivity and specificity of the analyses. All clinically-actionable SNV and InDel variant calls in genes covered by both panels (n = 17) were identified by both laboratories. This data supports the proposal that distinct gene panel designs and sequencing workflows are capable of making consistent variant calls in solid tumor FFPE-derived samples.     

白芍总甙联合曲安奈德局部涂擦治疗口腔扁平苔藓的临床探讨

目的 观察白芍总甙联合曲安奈德软膏局部涂擦治疗口腔扁平苔藓的临床疗效.方法 收集60例经临床及病理确诊为口腔扁平苔藓的患者,按就诊顺序单双号随机分为治疗组和对照组各30例.治疗组采用局部涂擦曲安奈德结合口服白芍总甙,对照组仅局部涂擦曲安奈德,两组患者均在治疗开始后第3个月观察疗效,并随访6个月后的复发率.结果 治疗3个月后复查：治疗组有效率83.3％,对照组有效率77％,两组比较无显著性差异（P＞0.05）.6个月后复查,治疗组复发率20％,对照组复发率52％.两组比较有统计学意义（P＜0.05）.结论 白芍总甙联合曲安奈德远期疗效优于单纯应用曲安奈德治疗口腔扁平苔藓.